Classifications of MDS and premalignant cytopenias
| Classification . | MDS subtypes or related conditions . |
|---|---|
| 2016 WHO classification (revised fourth edition)2 | • MDS with single-lineage dysplasia (MDS-SLD) • MDS with multilineage dysplasia (MDS-MLD) • MDS with ring sideroblasts, with single lineage dysplasia (MDS-RS-SLD) or multilineage dysplasia (MDS-RS-MLD) • MDS with isolated del(5q) (MDS del (5q)) • MDS with excess blasts (MDS-EB), type 1 (MDS-EB-1) or type 2 (MDS-EB-2) • MDS, unclassifiable (MDS-U) |
| International Consensus Classification (2022)17 | MDS subtypes • MDS with mutated SF3B1 (MDS-SF3B1) • MDS with del(5q) (MDS del(5q)) • MDS, NOS—without dysplasia • MDS, NOS—with single-lineage dysplasia • MDS, NOS—with multilineage dysplasia • MDS with excess blasts (MDS-EB) • MDS with mutated TP53 • MDS/AML |
| Related clonal disorders • Clonal hematopoiesis of indeterminate potential (CHIP) • Clonal cytopenia of undetermined significance (CCUS) • VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: autoinflammatory syndrome associated with anemia and clonal hematopoiesis due to somatic mutation in the UBA1 gene | |
| 2022 WHO classification (fifth edition)20 | MDS with defining genetic abnormalities • MDS with low blasts and isolated 5q deletion (MDS-5q) • MDS with low blasts and SF3B1 mutation (MDS-SF3B1) • MDS with biallelic TP53 inactivation (MDS-bi TP53) MDS, morphologically defined • MDS with low blasts (MDS-LB) • MDS, hypoplastic (MDS-h) • MDS with increased blasts (MDS-IB, including MDS with fibrosis) |
| Classification . | MDS subtypes or related conditions . |
|---|---|
| 2016 WHO classification (revised fourth edition)2 | • MDS with single-lineage dysplasia (MDS-SLD) • MDS with multilineage dysplasia (MDS-MLD) • MDS with ring sideroblasts, with single lineage dysplasia (MDS-RS-SLD) or multilineage dysplasia (MDS-RS-MLD) • MDS with isolated del(5q) (MDS del (5q)) • MDS with excess blasts (MDS-EB), type 1 (MDS-EB-1) or type 2 (MDS-EB-2) • MDS, unclassifiable (MDS-U) |
| International Consensus Classification (2022)17 | MDS subtypes • MDS with mutated SF3B1 (MDS-SF3B1) • MDS with del(5q) (MDS del(5q)) • MDS, NOS—without dysplasia • MDS, NOS—with single-lineage dysplasia • MDS, NOS—with multilineage dysplasia • MDS with excess blasts (MDS-EB) • MDS with mutated TP53 • MDS/AML |
| Related clonal disorders • Clonal hematopoiesis of indeterminate potential (CHIP) • Clonal cytopenia of undetermined significance (CCUS) • VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: autoinflammatory syndrome associated with anemia and clonal hematopoiesis due to somatic mutation in the UBA1 gene | |
| 2022 WHO classification (fifth edition)20 | MDS with defining genetic abnormalities • MDS with low blasts and isolated 5q deletion (MDS-5q) • MDS with low blasts and SF3B1 mutation (MDS-SF3B1) • MDS with biallelic TP53 inactivation (MDS-bi TP53) MDS, morphologically defined • MDS with low blasts (MDS-LB) • MDS, hypoplastic (MDS-h) • MDS with increased blasts (MDS-IB, including MDS with fibrosis) |
NOS, not otherwise specified.